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ABSTRACT
Background: Tretinoin and 5-fluorouracil are indicated for treatment of various skin disorders and ac-
tinic keratosis respectively.
Objective: Present study was focused to design liposomes containing 5- fluorouracil and tretinoin. De-
sign was further optimized by 32 full factorial design.
Methods: Liposomes were prepared by ethanol injection method and evaluated by Transmission Elec-
tron Microscopy, percentage entrapment efficiency, zeta potential and in vitro drug release. Optimized 
formulation was subjected to histopathological and stability studies at 4ºC, 25ºC and 60ºC temperatures.
Results: No drug crystals were visible in transmission electron microscopy, regardless of the preparation 
technique or the loaded drug. Formulation F9 showed maximum drug entrapment of 72.86% and 69.70% 
for 5-fluorouraciland tretinoin respectively. When phospholipid concentration was increased from 40 
to 60 mg/ml, encapsulation efficiencies of formulation increased. Zeta potential and particle size were 
maintained within range of -19.14 to -25.61 and 100 to 200 nm respectively which facilitated good sta-
bility and penetration of liposomes. Dissolution profiles of formulations F1 to F6 showed high amount 
of drug release (30.6 to 67.42%) at 2 h. Liposomes were not stable at high temperature but formulations 
were most stable when stored at lower temperature i.e. 4oC.
Conclusion: So, in liposomes both 5-fluorouracil and tretinoin were successfully incorporated and it can 
be further used for formulation development.
Keywords: 5-fluorouracil; Tretinoin; Liposomes; in vitro drug release; 32 experimental design.
RESUMEN
Objetivo: El presente estudio se centró en el diseño de liposomas que contenían 5-fluorouracilo y treti-
noína. El diseño fue optimizado por 32 diseño factorial completo.
Metodos: Los liposomas se prepararon mediante el método de inyección de etanol y se evaluaron me-
diante Microscopía Electrónica de Transmisión, % de eficiencia de encapsulación, potencial zeta y li-
beración de fármaco in vitro. La formulación optimizada se sometió a estudios histopatológicos y de 
estabilidad a temperaturas de 4ºC, 25ºC y 60ºC.
Resultados: Ningún cristal de los fármacos era visibles en el Microscopía Electrónica de Transmisión, sin 
importar la técnica de la preparación o el fármaco cargado. La formulación F9 demostró el atrapamiento 
máximo del fármaco del 72,86% y del 69,70% para 5-fluorouracilo y tretinoína respectivamente. Cuando 
la concentración del fosfolípido fue aumentada a partir de 40 a 60 mg/ml, las eficiencias de encapsu-
lación de la formulación aumentaron. El potencial de zeta y el tamaño de partícula fueron mantenidos 
dentro de la gama de-19,14 a -25,61 y 100 a 200 nanómetros respectivamente, que facilitó la buena esta-
bilidad y la penetración de liposomas. Los perfiles de disolución de las formulaciones F1 a F6 mostraron 
una alta cantidad de liberación de fármaco (30,6 a 67,42%) a las 2h. Los liposomas no eran estables a alta 
Artículo Original 
Original Article
Correspondencia 
Correspondence
Dr. Gaurav Tiwari,
Pranveer Singh Institute of Technology,
Kalpi Road, Bhauti,
Kanpur-208020,
Uttar Pradesh, India.
e-mail: drgauravtiwari81@gmail.com,
Conflicto de interés 
Competing interest
There is no conflict of interest
Received: 27.09.2018 
Accepted: 04.05.2019
Liposomal delivery of 5 Fluorouracil and Tretinoin: An Aspect of Top-
ical treatment of skin warts
Entrega liposomal de 5 fluorouracilo y tretinoína: un aspecto del tratamiento tópico 
de las verrugas cutáneas
Ruchi Tiwari1, Gaurav Tiwari1*, Ankita Wal1 and Chitranshu Gupta1
1 Department of Pharmaceutical Sciences, Pranveer Singh Institute of Technology, Kalpi road, Bhauti, Kanpur, Uttar Pradesh, India.
http://dx.doi.org/10.30827/ars.v60i3.7966
140 Ars Pharm. 2019; 60(3): 139-146
Tiwari R, et al.
temperatura, pero las formulaciones eran más estables cuando se 
almacenaban a una temperatura más baja, es decir, 4 ºC.
Concusiones: Así, en los liposomas, tanto los fármacos 5-fluorou-
racilo como los tretinoína se incorporaron con éxito y se pueden 
utilizar para el desarrollo de la formulación.
Palabras clave: 5 fluorouracilo; tretinoína; liposomas; liberación de 
fármaco in vitro; 32 diseño experimental.
INTRODUCTION
Liposomes are utilized as transporters for both lipophilic 
and water solvent molecules. Hydrophilic substances are 
encapsulated in the interior aqueous portions whereas li-
pophilic substances are entrapped within lipid bilayers. 
Liposomes as drug delivery frameworks plays a vital role 
to enhance their therapeutic effect, decrease adverse ef-
fects and improve the viability of medications for the treat-
ment of illnesses.(1) Liposomes are as of now increasingly 
involved in the dermatology, antibody adjuvant, infective 
ailment, immunology, eye issue, and in tumor treatment. 
Various improvements have been utilized to target lipos-
omes which lead to drug accumulation at disease sites 
and reduced distribution to sensitive tissues. Liposomes 
with enhanced drug delivery to disease locations, by the 
ability of long circulation residence times, are now achiev-
ing clinical acceptance.(2)Release rate of different types of 
drug molecules from liposomes is dependent on the type 
of drug applied.(2) Cholesterol may be included to improve 
bilayer characteristics of vesicles, increase microviscosity 
of the bilayers, reduce the permeability of the membrane 
to water-soluble molecules, stabilize the membrane and in-
crease the rigidity of the vesicles.(3)5- FU is most often pre-
scribed for actinic keratoses and skin warts.(2,3) It destroys 
sun-damaged skin cells so the skin appears smoother and 
more youthful. It works best on face and scalp, and is less 
effective on other areas. TTN enhances the effect of 5- FU by 
peeling off the top layer of skin. It reduces the time required 
for the course of 5- FU treatment.(3)
The present study was planned to formulate and evaluate 
a new combination of 5- FU and TTN for topical adminis-
tration. The main aim of the study is to attain effective drug 
concentration at the intended site of action for a sufficient 
period of time to elicit the response.
MATERIALS
TTN and 5- FU were kindly provided by Curetech Skin-
care [Baddi, Himachal Pradesh] and Shalaks pharmaceu-
ticals [New Delhi] respectively. Cholesterol and Soy Lec-
ithin were purchased from the Central drug house [New 
Delhi]. Cellophane membrane (molecular weight cut off 
12,000-14,000) was purchased from Qualigens Fine Chemi-
cals [Mumbai, India]. Ethanol and all other chemicals used 
were of analytical grade.
METHODS
Experimental design
A 32 randomized full factorial design was adopted to opti-
mize the variables. In the design two factors were evaluat-
ed, each at 3 levels and experimental trials were at all nine 
possible combinations using Design Expert Software 10 
(State-Ease, inc., Minneapolis, USA). In the present investi-
gation, the concentration of TTN (X1) and concentration of 
phospholipid (X2) were selected as independent variables. 
The entrapment efficiency (EE; R1), and cumulative drug 
release (% CDR; R2) were selected as dependent variables 
(Table 1). The polynomial equation was generated for the 
dependent variables. The value of p<0.05 was considered 
to be significant.(4,5)
Table 1: 32 Factorial design for preparation of liposomal formulations
Formulation 
Code#
Independent Variables
Dependent Variables
Zeta Potential
(mV)
Particle size (nm)
X1* X2$
F1
F2
F3
F4
F5
F6
F7
F8
F9
-1
0
+1
-1
0
+1
-1
0
+1
-1
-1
-1
0
0
0
+1
+1
+1
%EE (R1)
%DR (R2)
-19.14±2.12
-19.99±1.98
-20.10±2.01
-24.34±1.87
-19.89±2.87
-21.42 ±1.34
-24.32±1.23
-23.99±1.87
-25.61±2.03
112±2.76
100±2.34
148±2.10
198±1.99
200±1.59
167±2.37
196±2.02
182±2.88
191±2.98
*Concentration of TTN, $Concentration of phospholipid, #All batches contained 500 mg of 5- FU, 4mg/ml cholesterol. Coded values (-1, 
0, +1); Actual values (mg/ml) (X1= 0.25, 0.75, 1.0, X2= 20, 40, 60)
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Formulation of drug loaded liposomes
Drug loaded liposomes were prepared by a modified etha-
nol injection method.(4) Required amounts of phospholipids 
(20, 40, 60 mg/ml) and cholesterol (4 mg/ml) were dis-
solved in ethanol and different concentrations of TTN (0.25, 
0.75 and 1.0 % w/v) was added to the organic phase in-
dividually. Resulting organic phase was injected by means 
of a syringe pump to aqueous phase (500 mg of 5-FUwas 
added to the aqueous phase) under magnetic stirring at 45± 
2 °C. Spontaneous liposome formation occurred as soon 
as the ethanolic solution was in contact with the aqueous 
phase. Liposome suspension was then kept under stirring 
for 1h at room temperature to remove the traces of solvent. 
The unloaded drug was removed by ultracentrifugation of 
liposome suspension (Beckman, Miami, Florida, USA) at 
60,000 rpm for 1 hour and stored at 4°C.(4,5)
Evaluation of liposomes
Morphological study by transmission electron microscopy 
(TEM)
Liposome suspensions were imaged by using TEM (Philips 
CM120; Eindhoven, The Netherlands). A drop of the lipos-
ome suspension was placed onto a carbon-coated copper 
grid, forming a thin liquid film. The films were negatively 
stained with 2% phosphotungstic acid solution for 1 min-
ute. The excess of phosphotungstic solution was removed 
with a filter paper and stained samples were characterized 
by using an accelerating voltage of 80 kV.(6,7)
Zeta potential study
The particle size and the zeta potential of liposomes were 
determined by dynamic light scattering (DLS), using the 
Zetasizer (Malvern instruments, UK). Each sample was 
measured three times, after which the mean of the values 
was calculated. The measurement was performed at 25°C 
after an appropriate dilution with distilled water.(10-11)
Entrapment efficiency
5ml of liposome formulation was taken and transferred to a 
100 ml volumetric flask containing 25 ml of phosphate buff-
er (skin pH 6.8), then sonicated using an ultrasound bath 
for few minutes and filtered through a 0.45μm membrane 
filter. The filtrate was finally diluted with phosphate buffer 
(pH 6.8) and absorbance was recorded by Shimadzu 1700 
UV visible spectrophotometer at 266 and 340 nm respec-
tively for5- FU and TTN.(7)
In vitro drug release
In-vitro drug release study of liposomal formulations was 
performed using franz diffusion cells with diffusional 
area of 0.75 cm2. An egg membrane was placed between 
donor and receptor compartments. The receptor compart-
ment contained phosphate buffer pH 6.8 was continuously 
stirred by magnetic bead and maintained at temperatureof 
37 ± 1ºC. One ml liposomal suspension was loaded on the 
donor compartment. The drug concentrations in aliquot 
were withdrawn at different time intervals and analyzed at 
266 nm and340 nm against appropriate blank for 5-FU and 
TTN respectively, using UV -Vis spectrophotometer.(3-5) The 
kinetics of drug release from liposomes was determined by 
fitting the appropriate drug release data to zero order, first 
order, Higuchi equation, Hixson-Crowell equation and the 
Korsemeyer-Peppas model.(9)
Optimization of liposome using experimental design
Constraints, like maximizing entrapment efficiency and % 
drug release at the end of 8 hours as well as minimizing 
the particle size, were set as a goal to select the optimized 
formulation using Design expert software version 10 (Stat-
Ease, Inc., Minneapolis, USA).
Histopathological evaluation of optimized liposome
A section of goatskin was harvested from local commer-
cial supplier to evaluates histopathological condition in 
the presence of F9 liposomes. Harvested skin was shaved 
and placed on a Franz diffusion cell filled with phosphate 
buffer (pH 6.8 ± 0.10).Test group was treated with F9, while 
control group was treated with blank liposome for about 
eight hours. Exposed test and control tissues were fixed 
in 10% v/v neutral buffered formalin (pH 6.6) and were 
routinely processed in paraffin. Tissue sections of ~7 μm 
were cut on a glass slide and stained with hematoxylin-eo-
sin. These sections were examined under light microscope 
to detect tissue damage caused by the formulations during 
the permeation studies.
RESULTS AND DISCUSSION
Evaluation of prepared liposomes
Negative-strain TEM images showed that liposomes ob-
tained were spherical shaped, which could have an impact 
on drug-release. The particle size of drug-loaded liposomes 
was found to be 100 - 200 nm (Table 1). No drug crystals 
were visible in TEM-images, regardless of the preparation 
technique or the loaded drug (Figure 1).(12) All liposomes 
were negatively charged and zeta-potential values varied 
between -19.14 and -25.61 mV (Table 1), which is consid-
ered as an optimal potential for assuring particle stability. 
It was observed that £ potential of prepared liposomes has 
sufficient charge to inhibit aggregation of vesicles.(13) The 
average percent drug entrapment efficiency of the nine for-
142 Ars Pharm. 2019; 60(3): 139-146
Tiwari R, et al.
mulations ranges from 28.57 to 72.86% and 37.88 to 69.70% 
of 5- FU and TTN respectively, where the Formulation 
F9 showed a maximum drug entrapment of 72.86% and 
69.70% for 5- FU and TTN respectively.
Figure 1: TEM image of formulation F9 at 10 kv, X5,000
In vitro Release Study of Liposomes
The release profiles of liposomes of entire formulations 
were shown in Figure 2. As the concentration of phospho-
lipid was increased from 20 to 60 mg/ml (Figure 2), using 
the same cholesterol percentage with respect to phospho-
lipid amount, the cumulative released amount of drugs 
decreased. It has been stated that the release of lipophilic 
agents from liposomes is delayed because of their location 
within the lipid bilayers.(10) From the drug release profile 
of formulations F2, F5, F8 it was observed that drug re-
lease was found to be increased within 2 hrs and very less 
amount of drug was left for further release. Release pro-
file of formulation F9 showed that almost entire drug was 
released within 7hrs. The higher amount of phospholipid 
in F9 leads to a time-dependent increase in diffusion co-
efficient is a highly lipophilic drug, should be entrapped 
within the phospholipid bilayers. Hence, the release mech-
anism involves slow diffusion through the liposome wall. 
No sudden release occurred during the release study, in-
dicating that no liposome disintegration had taken place. 
In vitro dissolution studies showed that as the concentra-
tion of phospholipid was increased, drug release rate was 
decreased. Dissolution profiles of formulations F1 to F6 
were not good because high amount of drug release (30.6 
to 67.42%) at 2 h. The results of drug release profile of the 
F9 showed the release of 32.48% of drug during initial 2hrs. 
While within the first 4 h 61.1% of drug was released and 
the remaining drug was released during last 4 hrs. Mod-
el with the highest correlation coefficient (r2) was judged 
to be a more appropriate model for the dissolution data. 
According to the result obtained by release kinetics in case 
of 5- FU formulations F1, F3, F4, F5, F7, and F8 followed 
the korsemeyer- peppas model, F2&F6 Hixson model, and 
F9 zero order kinetics. In case of TTN F1, F3, F5,F6, F8&F9 
followed korsemeyer- peppas model, F2&F7 zero and F4 
Higuchi kinetics.(16)
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(A)
(B)
Figures 2: Drug Release profiles of (A) 5- FUand (B) TTN
Optimization of Liposome Formulation Using 32 Full 
Factorial Design
A 32 full factorial design was constructed to study the effect 
of TTN concentration (X1) and phospholipid concentration 
(X2) on the drug release from liposomal preparations. The 
percentage entrapment efficiency at pH 6.8 (R1) and per-
centage drug release (R2) was selected as dependent var-
iables. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high 
value. The statistical model incorporating interactive and 
polynomial terms was utilized to evaluate the responses. 
The interaction terms (X1, X2) showed how the response 
changes when 2 factors are changed simultaneously. The 
full Equation (equation containing only statistically sig-
nificant terms) is then used for drawing plots to visualize 
the impact of changing variables at a glance. The optimum 
point may be identified from the plot.
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The factorial equation for R1 (Eq 1) and R2 (Eq2) was found 
to be:
R1=7.87+0.47x1+0.47x2+0.67x1x2+0.67x1+0.67x2 2 
……………………….. Eq 1
R2=51.07+0.47x1+0.47x2+0.67x1x2+0.67x1+0.67x2 2 
……………………….. Eq 2
The coefficient of X1 and X2 was found to be positive in-
dicated that predicted values could be obtained when the 
concentration of TTN and phospholipid increased. The p 
value for variable X1 and X2 was 0.0231 and 0.0112 respec-
tively (P<0.0500) indicated that both independent variables 
showed a significant effect on dependent variable i.e. R1 
and R2. The prediction error in the response parameters 
ranged between 0.47 and 0.79% to the value of the absolute 
error of 0.90±0.70%. The low values of error indicate the 
high prognostic ability of factorial equation and counter 
plot methodology. “Adeq Precision” measures the signal 
to noise ratio. A ratio greater than 4 is desirable. The ra-
tio of 7.56 indicates an adequate signal. Thus, this model 
can be used to navigate the design space(6). From the plot, 
the spread of points on the right side of the graph (where 
X1 is low) is larger than the spread between the points at 
the left side of the graph where X1 is high. In other words, 
the effect of X2 is less significant where X1 is high (Figure 
3(A)).(17,18) Therefore, at a very high X1 value, the effect of 
phospholipid concentration can be significantly reduced, 
thus reducing the R1 and R2. Ramps (Figure 3(B)) indicated 
that response R1 increases with a decrease in X1 and X2.(19) 
Higher X1 and X2 reduced response R1.Ramps report clear-
ly supported optimized formulation. After generating the 
polynomial equation for the dependent and independent 
variables, the combination was optimized for responses.(20) 
Formulations with high X1 and X2 showed highest desir-
ability factor of 1.00 with highest R1 and R2 was selected 
as optimized formulation (Figure 3(C)). The Response Sur-
face linear model generated for X1 and X2 was found to 
be significant with an F-value of 2.50 and 6.80 (P<0.0500) 
respectively.
Figure 3: Graphs showing experimental design (A) Interaction of R1 and R2; (B) Ramps for Desirability; (C) 3D graph for optimization 
of independent variables
145Ars Pharm. 2019; 60(3): 139-146
Liposomal delivery of 5 Fluorouracil and Tretinoin: An Aspect of Topical treatment of skin warts
The histopathology results demonstrated the safety profile 
of developed F9 liposomes (Figure 4). The developed lipos-
ome F9 revealed no signs of damage to epithelial cells of 
goatskin.
Figure 4: Histopathology of goatskin treated with (A) control and; 
(B) F9 liposome formulation
CONCLUSION
In this study, liposomes containing 5- FU and TTN were 
prepared with different proportions of TTN and phospho-
lipid using modified injection method. Liposomes com-
posed of 1.0 mg/ml of TTN and 60 mg/ml phospholipid 
presented higher % entrapment efficiency and 30 days sta-
bility. Particle size of liposomes remained smaller than 200 
nm, making them suitable for topical application. Results 
suggested that liposomes gradually release 5- FU and TTN 
and found to be topically safe as tested by histological eval-
uation. Prepared liposomes containing 5-FU and TTN may 
be successfully used for treatment of skin warts with high 
patient compliance.
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